| Product name | Recombinant Human FGF-19 Protein |
|---|---|
| Catalog No. | RP01231 |
| Description | Recombinant Human FGF-19 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Phe27-Lys216) of human FGF-19 (Accession #NP_005108.1) fused with a 6×His tag at the C-terminus. |
| Bio-Activity | Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human FGF19 at 5 μg/mL (100 μL/well) can bind Recombinant Human FGFR4 with a linear range of 0.9-3.8 μg/mL. |
| Purity | > 97% by SDS-PAGE. |
| Endotoxin | < 0.1 EU/μg of the protein by LAL method. |
| Formulation | Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.Contact us for customized product form or formulation. |
| Species | Human |
| Calculated MW | 22.09 kDa |
| Synonym | FGF19 |
|---|---|
| Expression Host | HEK293 cells |
| Tag | C-His |
| Swiss-Prot | |
| Gene ID |
| Storage | Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt. After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week. |
|---|---|
| Reconstitution | Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles. |
* For research use only. Not for therapeutic or diagnostic purposes.
Publishing research using RP01231? Please let us know so that we can cite the reference in this datasheet.
